<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29617499</article-id><article-id pub-id-type="pmc">5873776</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0132</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Mortality Predictors in the Surgical Treatment of Active Infective
Endocarditis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>de Oliveira</surname><given-names>Jenny Lourdes Rivas</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib><contrib contrib-type="author"><name><surname>dos Santos</surname><given-names>Magaly Arrais</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Arnoni</surname><given-names>Renato Tambellini</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Ramos</surname><given-names>Auristela</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Togna</surname><given-names>Dorival Della</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Ghorayeb</surname><given-names>Samira Kaissar</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Kroll</surname><given-names>Roberto Tadeu Magro</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>de Souza</surname><given-names>Luiz Carlos Bento</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><aff id="aff1">
<label>1</label> Instituto Dante Pazzanese de Cardiologia, S&#x000e3;o Paulo, SP,
Brazil. </aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Jenny Lourdes Rivas de Oliveira, Instituto
Dante Pazzanese de Cardiologia, Av. Dr. Dante Pazzanese, 500 - Vila Mariana -
S&#x000e3;o Paulo, SP, Brazil - Zip code: 04012-909. E-mail:
<email>jennyr16@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2018</year></pub-date><volume>33</volume><issue>1</issue><fpage>32</fpage><lpage>39</lpage><history><date date-type="received"><day>21</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>14</day><month>7</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Active infective endocarditis is associated with high morbidity and
mortality. Surgery is indicated in high-risk conditions, and the main
determinants of mortality in surgical treatment should be evaluated.</p></sec><sec><title>Objective</title><p>To identify mortality predictors in the surgical treatment of active
infective endocarditis in a long-term follow-up.</p></sec><sec><title>Methods</title><p>This prospective observational study involved 88 consecutive patients
diagnosed with active infective endocarditis, who underwent surgery between
January 2005 and December 2015. Fifty-eight (65.9%) patients were male, the
mean age was 50.87&#x000b1;16.15 years. A total of 31 (35.2%) patients had a
history of rheumatic fever; 48 (54.5%) had had heart surgery with prosthetic
valve implantation; 45 (93.8%) had biological prosthetic valve endocarditis
and 3 (6.3%) mechanical prosthetic valve; 40 (45.5%) patients had the
disease in their native valve. The mean EuroSCORE II was 8.9&#x000b1;6.5%,
and the main surgical indication was refractory heart failure in 38 (43.2%)
patients. A total of 68 bioprosthesis (36 aortic, 32 mitral) and 29
mechanical prostheses (12 aortic, 17 mitral) were implanted and three mitral
valve plasties performed. A total of 25 (28.4%) patients underwent double or
triple valve procedures. Aortic annulus reconstruction by abscess was
performed in 18 (20.5%) and six (6.81%) patients had combined procedure. The
mean surgery time was 359&#x000b1;97.6 minutes.</p></sec><sec><title>Results</title><p>The overall survival in up to a 10-year follow-up period was 79.5%. In the
univariate analysis, the main mortality predictors were positive blood
cultures (<italic>P</italic>=0.003), presence of typical microorganisms
(<italic>P</italic>=0.008), most frequently <italic>Streptococcus
viridans</italic> (12 cases; 25%); C-reactive protein (hazard ratio
[HR] 1.034, 95% confidence interval [CI] 1.000
to 1.070, <italic>P</italic>=0.04); creatinine clearance (HR 0.977, 95% CI
0.962 to 0.993, <italic>P</italic>=0.005); length of surgery: every five
minutes multiplies the chance of death 1.005-fold (HR 1.005, 95% CI 1.001 to
1.009, <italic>P</italic>=0.0307); age (HR 1.060, 95% CI 1.026 to 1.096,
<italic>P</italic>=0.001); and EuroSCORE II (HR 1.089, 95% CI 1.030 to
1.151, <italic>P</italic>=0.003).</p></sec><sec><title>Conclusion</title><p>A positive blood culture with typical microorganism, C-reactive protein, age,
EuroSCORE II, total surgical time and the presence of postoperative
complications were the major predictors of mortality and significantly
impacted survival in up to a 10-year follow-up period.</p></sec></abstract><kwd-group><kwd>Endocarditis, Bacterial</kwd><kwd>Heart Valves</kwd><kwd>Cardiovascular Surgical Procedures</kwd><kwd>Heart Valve Prosthesis Implantation</kwd><kwd>Mortality</kwd></kwd-group></article-meta></front><body><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="20%" span="1"/><col width="80%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Atrial fibrillation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AFRVR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Atrial fibrillation with
rapid ventricular response</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AIE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Active infective
endocarditis</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">BMI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Body mass index</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Confidence interval</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CRP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= C-reactive protein</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CKD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Chronic kidney
disease</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">DM</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Diabetes mellitus</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Hazard ratio</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Infective
endocarditis</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular
ejection fraction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PASP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Pulmonary artery
systolic pressure</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PH</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Pulmonary
hypertension</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1"> SH</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Systemic
hypertension</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Patients with valvulopathies, particularly those of rheumatic etiology, mitral valve
prolapse with insufficiency, and degenerative aortic valve disease or those of
bicuspid origin, cardiac valve prostheses, valvulopathies corrected with prosthetic
materials, prior endocarditis episodes and congenital heart disease are considered
at risk of developing severe infective endocarditis (IE)<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.</p><p>The main indications for the surgical treatment of IE are refractory heart failure
and annular abscess formation<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>]</sup>. Other
indications are persistent bacteremia after five to seven days of treatment with
appropriate antibiotics, persistent vegetation or vegetation greater than 10 mm,
severe valvular regurgitation, mycotic endocarditis and multiresistant
microorganisms<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref>]</sup>.</p><p>The surgical treatment of IE involves valvular repair of lesions limited to leaflets,
replacing the valve with a prosthetic or annular reconstruction with the use of a
pericardial patch and Dacron prosthetic graft in cases of greater impairment, such
as in the case of annular abscess<sup>[<xref rid="r5" ref-type="bibr">5</xref>-<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p><p>In terms of patients evolution with active infective endocarditis (AIE), surgery is a
protective factor and has been associated with a significant reduction in mortality
in the longterm follow-up of these patients when compared with patients who remained
in clinical treatment<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>.</p><p>In patients with AIE in a native valve, congestive heart failure and emergency
surgery are considered independent risk factors for mortality; emergency surgery is
also an independent risk factor for patients with prosthetic
endocarditis<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>.</p><p>The survival of patients undergoing surgical treatment of IE in the native valve is
greater than that of those with prosthetic valve IE<sup>[<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r9" ref-type="bibr">9</xref>]</sup>. Independent
postoperative mortality predictors also include paravalvular abscesses,
<italic>Staphylococcus aureus</italic> as the etiologic agent and a left
ventricular ejection fraction (LVEF) lower than 40%<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p><p>Dohmen et al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>
reported a significant difference in hospital mortality in relation to gender, with
23% mortality in females <italic>vs.</italic> 15% in males
(<italic>P</italic>=0.01). Furthermore, age, the involvement of several valves and
the need for preoperative dialysis are also major mortality risk
factors<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>In a study of patients with aortic valve IE, dialysis patients with chronic kidney
disease (CKD) and those who needed aortic annulus reconstruction had high
postoperative mortality<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. Another study of patients with IE in an isolated mitral
valve showed worse event-free survival in those who had prosthetic mitral valve
endocarditis; furthermore, preoperative shock, <italic>Staphylococcus
aureus</italic> infection and bioprosthesis implantation were independent
predictors of all-cause mortality. These outcomes were associated with the fact that
bioprosthetic patients were older than the group of patients with mechanical
prostheses<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p><p>The need for simultaneous aortic and mitral valve intervention is common in IE and is
related to increased technical difficulty. Studies have reported high postoperative
morbidity and mortality in the short and long terms in these patients, with hospital
mortality rates of up to 15.6% and late mortality rates of 32.2%<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>.</p><p>However, in cases of endocarditis, early intervention, <italic>i.e.</italic>, within
the first 48 hours of hospitalization, has resulted in significant reductions in
embolic events and all-cause mortality when compared with a conventional treatment
group<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>.</p><p>In-hospital mortality of AIE patients undergoing surgical treatment is high as a
result of sepsis development<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. Preoperative, intraoperative and postoperative factors
are associated with worse survival. This study identifies mortality predictors in
the surgical treatment of AIE in a long-term follow-up.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This prospective observational study involved 88 consecutive adult patients with a
definite or possible diagnosis of IE according to the modified Duke
criteria<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>
who underwent surgery between January 2005 and December 2015. The clinical follow-up
was concluded in December 2016, with a loss of 9.09%. Patients under 18 years of age
and those whose IE diagnosis was rejected by the modified Duke criteria were
excluded. This study was approved by the Institutional Research Ethics Committee
under number CAAE 62465816.2.0000.5462.</p><p>Data collection was conducted in regard to demographic characteristics, personal
pathological history, predisposing heart disease, laboratory test results, blood
cultures, echocardiography, risk stratification according to EuroSCORE II, analysis
of the modified Duke criteria, classifying patients as having definitive or possible
diagnoses, surgical intervention characteristics and early and late postoperative
progress.</p><p>The primary outcomes were hospital mortality, late mortality and determination of the
main factors associated with increased mortality. Secondary outcomes were
reoperation rates due to recurrence of endocarditis in up to a 10-year follow-up
period.</p><p>All patients underwent median sternotomy with extracorporeal circulation. Hypothermic
cardiopulmonary bypass was established at 32&#x000ba;C. All patients received central
cannulation. The aorta was cross-clamped and cold blood or cold crystalloid
(Custodiol<sup>&#x000ae;</sup>) cardioplegia was used for myocardial protection
with antegrade flow. Transverse aortotomy was performed 3.5 cm above the right
coronary ostium for aortic valve replacement. Radical debridement of infected tissue
and aortic root abscess cavity was performed. Bovine pericardial or Dacron
prosthetic graft was used for stabilization of the infected area and aortic annulus.
Aortic annulus enlargement was performed using the Manouguian technique in small
aortic annulus cases. The mitral valve was exposed through a right-sided left
atriotomy, the basic surgical principle was radical resection of all infected
valvular and subvalvular tissue, and mitral valve replacement or repair was
performed when indicated. Right atriotomy was performed for the repair of the
tricuspid valve (tricuspid valve annuloplasty). Associated procedure was performed
in six patients, including epicardial permanent pacemaker implantation,
atrioseptoplasty, ventriculoseptoplasty and subaortic membrane resection and
radiofrequency ablation procedure.</p><sec><title>Statistical Analysis</title><p>Categorical variables are expressed as absolute and relative frequencies and
continuous variables as means, medians and standard deviations, with minima and
maxima when indicated. The Mann-Whitney test was used for comparisons between
groups, the Kaplan-Meier and Cox Model methods were used for survival analysis
and mortality predictors, and the Log-Rank Test was used to evaluate differences
between the curves. A value of <italic>P</italic>&#x0003c;0.05 was considered
statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Of the 88 patients, 58 (65.9%) were male, the mean age was 50.87&#x000b1;16.15 years
(17-87 years) and the mean body mass index (BMI) was 24.86&#x000b1;3.72
kg/m<sup>2</sup> (16.16 to 37.72 kg/m<sup>2</sup>, median 24.14
kg/m<sup>2</sup>). There was a history of rheumatic fever in 31 (35.2%) patients;
prior endocarditis in four (4.5%) patients; prior cardiac surgery with prosthetic
valve implantation in 48 (54.5%) patients, of whom 27 (56.30%) had the surgery at
our institution and 21 (43.8%) at other centers; and 22 (45.80%) patients with
intervals between prior surgery and new surgery of less than or equal to 1 year, and
26 (54.2%) patients with intervals of greater than one year. Bioprosthetic
endocarditis was observed in 45 (93.8%) patients, and three (6.3%) patients had
mechanical prosthetic endocarditis. The prosthesis of the majority of patients with
prosthetic endocarditis was in the mitral position (23 patients; 47.9%), followed by
the aortic position (20 patients; 41.7%), and there were only five (10.4%) patients
with endocarditis in mitral and aortic prostheses simultaneously.</p><p>Native valve endocarditis occurred in 40 (45.5%) patients, most often in the mitral
valve (19 patients; 47.5%); 13 (32.5%) cases occurred in the aortic valve and four
(10%) in the aortic and mitral valves. Personal medical history findings were as
follows: systemic hypertension (SH) was observed in 13 (14.8%) patients, diabetes
mellitus (DM) in 17 (19.3%), and CKD in 17 (19.3%); six (6.8%) patients were on
dialysis, 18 (20.5%) had atrial fibrillation (AF), four (4.5%) were intravenous drug
users and seven (8%) had a permanent pacemaker. The mean EuroSCORE II was
8.9&#x000b1;6.5% (1.3 to 32.8%, median 6.8%).</p><p>Preoperative laboratory tests were as follows: mean hemoglobin, 11.19&#x000b1;2.26
mg/dL (6.6 to 16.8 mg/dL, median 11 mg/dL); leukocytes, 11.176&#x000b1;5.208
mm<sup>3</sup> (2.300-32.500 mm<sup>3</sup>, median 10.375 mm<sup>3</sup>); mean
C-reactive protein (CRP), 8.67&#x000b1;10.57 mg/dL (0.07 to 56 mg/dL, median 5.20);
mean creatinine, 1.47&#x000b1;1.56 mg/dL (0.48 to 12.40 mg/L, median 1 mg/dL); mean
creatinine clearance, 75.81&#x000b1;34.21 mL/min (7-168 mL/min, median 73 mL/min);
and mean blood glucose, 108.03&#x000b1;40.34 mg/dl (61-331 mg/dl, median 97 mg/dL).
Microbiological study revealed the following: 50 (56.8%) patients with positive
blood cultures and typical microorganisms in 48 (54.5%) patients, most frequently
<italic>Streptococcus viridans</italic> in 12 (25%) cases and
<italic>Staphylococcus epidermidis</italic> in 10 (20.83%).</p><p>The main preoperative echocardiography findings were as follows: mean LVEF of
60.61&#x000b1;10.98% (24-84%, median 64%) and pulmonary hypertension (PH) in 62
(70.5%) patients, of which 23 (37.10%) cases were mild, 22 (35.50%) moderate and 17
(27.40%) severe. There was a mean pulmonary artery systolic pressure (PASP) of
48.09&#x000b1;17.56 mmHg (29-91 mmHg, median 46.50 mmHg). Vegetation was found in 66
(75%) patients, with a mean size of 13.77&#x000b1;6.7 mm (1.9 to 35 mm, median 12
mm); 50 (75%) patients had vegetation over 10 mm, and 15 patients had two or more
vegetations. A total of 11 (12.5%) patients had abscesses.</p><p>The mean preoperative hospitalization time was 21&#x000b1;19.15 days (1-98 days,
median 16 days). Emergency surgery (first 24 hours) was performed on five (5.7%)
patients, urgent (24-48 hours) on 10 (11.4%) patients and elective (after 48 hours)
on 73 (83%) patients. The principal surgical indication was refractory heart failure
in 38 (43.2%) patients. There was a definitive diagnosis in 62 (70.5%) patients and
a possible diagnosis in 26 (29.5%) according to the modified Duke criteria. The
sample's main preoperative clinical characteristics are shown in <xref ref-type="table" rid="t1">Table 1</xref>.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Preoperative clinical characteristics of the sample.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables&#x000a0;</th><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Total Population n=88</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value Mortality</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">50.86&#x000b1;16.15</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="2" colspan="1">Gender</td><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">58 (65.9%)</td><td align="center" rowspan="2" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">30 (34.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">24.86&#x000b1;3.72</td><td align="center" rowspan="1" colspan="1">0.43</td></tr><tr><td align="left" rowspan="1" colspan="1">SH</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">13 (14.8%)</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">DM</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">17 (19.3%)</td><td align="center" rowspan="1" colspan="1">0.35</td></tr><tr><td align="left" rowspan="1" colspan="1">CKD</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">17 (19.3%)</td><td align="center" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior heart surgery</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">48 (54.5%)</td><td align="center" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" rowspan="2" colspan="1">Interval between prior and new surgery</td><td align="left" rowspan="1" colspan="1">&#x02264; 1 year</td><td align="center" rowspan="1" colspan="1">22 (45.8%)</td><td align="center" rowspan="2" colspan="1">0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e; 1 year</td><td align="center" rowspan="1" colspan="1">26 (54.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">IV drug users</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">4 (4.5%)</td><td align="center" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1">AF</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">18 (20.5%)</td><td align="center" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEF &#x02264;50%</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">19 (21.59%)</td><td align="center" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">PH&#x02265;50 mmHg</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">39 (44.3%)</td><td align="center" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="3" colspan="1">NYHA</td><td align="left" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">38 (43.2%)</td><td align="center" rowspan="3" colspan="1">0.84</td></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">41 (46.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">9 (10.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">EuroSCORE II</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">8.9%&#x000b1;6.5%</td><td align="center" rowspan="1" colspan="1">0.03</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>AF=atrial fibrillation; BMI=body mass index; CKD=chronic kidney disease;
DM=diabetes mellitus; IV=intravenous; LVEF=left ventricular ejection
fraction; NYHA=New York Heart Association; PH=pulmonary hypertension;
SH=systemic hypertension</p></fn></table-wrap-foot></table-wrap><p>A total of 68 (77.27%) bioprostheses (36 in the aortic position, 32 mitral), 29
(22.72%) mechanical prostheses (12 in the aortic position, 17 mitral) were implanted
and three (3.4%) mitral valve plasties were performed. A total of 11 (12.5%)
patients underwent procedures on the tricuspid valve, eight patients in combination
with aortic or mitral surgery, and three (3.4%) had isolated tricuspid valve
plasties. A total of 25 (28.4%) patients underwent double or triple valve
procedures. Aortic annulus reconstruction by abscess with bovine pericardial patch
or Dacron prosthetic graft was performed on 18 (20.5%) patients, aortic annulus
enlargement was performed using the Manouguian technique in three (3.4%) patients
and mitral valve annulus reconstruction was performed on four (4.5%). Only six
(6.81%) patients had a combined procedure, epicardial permanent pacemaker
implantation in three patients, atrioseptoplasty in one patient,
ventriculoseptoplasty and subaortic membrane resection in one patient and surgical
ablation of AF in one patient. The mean surgery time was 359&#x000b1;97.6 min
(180-840, median 351 min)</p><p>The mean follow-up time was 4.5&#x000b1;3 years (0.04 to 11.6 years), and the mean
survival time was 9.06&#x000b1;0.54 years (7.99 to 10.30 years). The overall survival
in up to a 10-year follow-up period was 79.5%. There was in-hospital mortality
within 30 days in 17.05% (15 patients); the leading cause of death was sepsis, in 13
(86.7%) patients (<italic>P</italic>=0.0001); late mortality was observed in 3.45%
(3 patients) due to cardiogenic shock (<italic>P</italic>=0.0001) and one patient
after reoperative complications regarding mitral and aortic bioprosthesis
dysfunction 7.34 years after implantation (<xref ref-type="fig" rid="f1">Figure
1</xref>).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Survival curves of patients with active infective endocarditis undergoing
surgical treatment.</p></caption><graphic xlink:href="rbccv-33-01-0032-g01"/></fig>
</p><p>The mean total hospitalization time was 47.25 days (interquartile range: 25.50 to
57.75 days) and was not significant in regard to mortality
(<italic>P</italic>=0.48).</p><p>In the univariate analysis, the major mortality predictors in the preoperative period
were positive blood cultures (32% <italic>vs.</italic> 6.25%,
<italic>P</italic>=0.003); the presence of typical microorganisms (31.25%
<italic>vs.</italic>. 7.5%, <italic>P</italic>=0.008); CRP, in which each 1
mg/dL increased the chance of death 1.034-fold (hazard ratio [HR]
1.034, 95% confidence interval [CI] 1.000 to 1.070,
<italic>P</italic>=0.04); creatinine, in which each 1 mg/dL increased the chance of
death 1.291-fold (HR 1.291, 95% CI 1.108 to 1.504, <italic>P</italic>=0.01); and
creatinine clearance, in which each increase of 1 mL/min decreased the chance of
death 0.977fold (HR 0.977, 95% CI 0.962 to 0.993, <italic>P</italic>=0.005). Other
factors that demonstrated statistically significant relationships with mortality
were SH (61.54% <italic>vs.</italic> 13.3%, <italic>P</italic>=0.0001); age, in
which each year multiplied the chance of death 1.060-fold (HR 1.060, 95% CI 1.026 to
1.096, <italic>P</italic>=0.001), with a significant correlation between SH and age
(<italic>P</italic>=0.0002); and EuroSCORE II, in which each 1% increased the
chance of death 1.089-fold (HR 1.089, 95% CI 1.030 to 1.151,
<italic>P</italic>=0.003).</p><p>In the postoperative period, 45 (51.1%) patients had complications, with a
significant impact on mortality (37.78% <italic>vs.</italic> 2.32%,
<italic>P</italic>=0.001); sepsis was observed in 19 (21.6%) patients (89.47%
<italic>vs.</italic> 1.44%, <italic>P</italic>=0.001); shock in 17 (19.3%)
patients (94.12% <italic>vs.</italic> 2.81%, <italic>P</italic>=0.001), with mixed
shock (cardiogenic and septic) in eight (9.1%), septic shock in seven (8%) and
vasoplegic shock in two (2.3%) patients; atrial fibrillation with rapid ventricular
response (AFRVR) was observed in 15 (17%) patients (0 <italic>vs.</italic> 22.78%,
<italic>P</italic>=0.133); CHB in five (5.7%) patients (40% <italic>vs.</italic>
19.27%, <italic>P</italic>=0.211); ventricular arrhythmia in four (4.5%) patients
(25% <italic>vs.</italic> 20.23%, <italic>P</italic>=0.791); permanent pacemaker in
three (3.4%) patients (33.33% <italic>vs.</italic> 20%, <italic>P</italic>=0.465);
surgical site infection in three (3.4%) patients (0 <italic>vs.</italic> 15.30%,
<italic>P</italic>=0.449); embolic events in two (2.27%) patients; septic
pulmonary embolism in 1 patient (100% <italic>vs.</italic> 0,
<italic>P</italic>=0.003); and ischemic stroke in one patient (0
<italic>vs.</italic> 15.66%, <italic>P</italic>=0.650). The anatomopathological
results with signs of IE occurred in 35 (39.8%) patients (25.71%
<italic>vs.</italic> 16.98%, <italic>P</italic>=0.222) (<xref ref-type="table" rid="t2">Table 2</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Postoperative complications.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Population</th><th align="center" colspan="2" rowspan="1">Death n=18</th><th align="center" rowspan="2" colspan="1"><italic>P</italic> value</th></tr><tr><th align="center" rowspan="1" colspan="1">&#x000a0;total n=88</th><th align="center" rowspan="1" colspan="1">Presence of variable</th><th align="center" rowspan="1" colspan="1">Absence of variable</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Postoperative complication</td><td align="center" rowspan="1" colspan="1">45 (51.1%)</td><td align="center" rowspan="1" colspan="1">17 (37.78%)</td><td align="center" rowspan="1" colspan="1">1 (2.32%)</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Sepsis</td><td align="center" rowspan="1" colspan="1">19 (21.6%)</td><td align="center" rowspan="1" colspan="1">17 (89.47%)</td><td align="center" rowspan="1" colspan="1">1 (1.44%)</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Shock</td><td align="center" rowspan="1" colspan="1">17 (19.3%)</td><td align="center" rowspan="1" colspan="1">16 (94.12%)</td><td align="center" rowspan="1" colspan="1">2 (2.81%)</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">AFRVR</td><td align="center" rowspan="1" colspan="1">15 (17%)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">18 (22.78%)</td><td align="center" rowspan="1" colspan="1">0.133</td></tr><tr><td align="left" rowspan="1" colspan="1">CHB</td><td align="center" rowspan="1" colspan="1">5 (5.7%)</td><td align="center" rowspan="1" colspan="1">2 (40%)</td><td align="center" rowspan="1" colspan="1">16 (19.27%)</td><td align="center" rowspan="1" colspan="1">0.211</td></tr><tr><td align="left" rowspan="1" colspan="1">Ventricular arrhythmia</td><td align="center" rowspan="1" colspan="1">4 (4.5%)</td><td align="center" rowspan="1" colspan="1">1 (25%)</td><td align="center" rowspan="1" colspan="1">17 (20.23%)</td><td align="center" rowspan="1" colspan="1">0.791</td></tr><tr><td align="left" rowspan="1" colspan="1">Permanent pacemaker</td><td align="center" rowspan="1" colspan="1">3 (3.4%)</td><td align="center" rowspan="1" colspan="1">1 (33.33%)</td><td align="center" rowspan="1" colspan="1">17 (20%)</td><td align="center" rowspan="1" colspan="1">0.465</td></tr><tr><td align="left" rowspan="1" colspan="1">Septic pulmonary embolism</td><td align="center" rowspan="1" colspan="1">1 (1.13%)</td><td align="center" rowspan="1" colspan="1">1 (100%)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">Ischemic stroke</td><td align="center" rowspan="1" colspan="1">1 (1.13%)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">18 (15.66%)</td><td align="center" rowspan="1" colspan="1">0.650</td></tr><tr><td align="left" rowspan="1" colspan="1">Surgical site infection</td><td align="center" rowspan="1" colspan="1">3 (3.4%)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">18 (15.30%)</td><td align="center" rowspan="1" colspan="1">0.449</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>AFRVR=atrial fibrillation with rapid ventricular response; CHB=complete
heart block</p></fn></table-wrap-foot></table-wrap><p>However, other variables evaluated in the univariate analysis showed no statistically
significant differences in mortality, as follows: native valve endocarditis or that
in a prosthetic valve (17.95% <italic>vs.</italic> 22.44%, <italic>P</italic>=0.55);
interval between prior and new surgery &#x02264;1 year or &#x0003e;1 year (22.72%
<italic>vs.</italic> 23.07%, <italic>P</italic>=0.95); presence of abscesses
(18.18% <italic>vs.</italic> 20.77%, <italic>P</italic>=0.98%); presence of
vegetation (19.70% <italic>vs.</italic> 22.72%, <italic>P</italic>=0.76); emergency,
urgent and elective surgery categories (20%, 10% and 21.92%, respectively,
<italic>P</italic>=0.76); the need for annular reconstruction (27.78%
<italic>vs.</italic> 18.57%, <italic>P</italic>=0.263); definitive or possible
diagnosis according to the modified Duke criteria (24.19% <italic>vs.</italic>
24.44%, <italic>P</italic>=0.214); valve position: mitral <italic>vs.</italic>
aortic <italic>vs.</italic> tricuspid <italic>vs.</italic> mitral with aortic and
tricuspid <italic>vs.</italic> mitral with aortic <italic>vs.</italic> mitral with
tricuspid (33.33% <italic>vs.</italic> 17.65% <italic>vs.</italic> 20%
<italic>vs.</italic> 14.29% <italic>vs.</italic> 21.88% <italic>vs.</italic>
66.67%, <italic>P</italic>=0.55); number of implanted valves single
<italic>vs.</italic> double <italic>vs.</italic> triple (20.63%
<italic>vs.</italic> 18.18% <italic>vs.</italic> 33.33%,
<italic>P</italic>=0.87) and isolated <italic>versus</italic> combined procedures
(19.51% <italic>vs.</italic> 33.33%, <italic>P</italic>=0.42).</p><p>In the multivariate analysis, when the preoperative variables positive blood culture,
presence of typical microorganisms, CRP, creatinine clearance, SH and age were
compared, it was evident that SH was a risk factor (HR 5.194, 95% CI 1.268 to
21.266, <italic>P</italic>=0.022) and that creatinine clearance offered a greater
mortality protection factor (HR 0.978, 95% CI 0.958 to 0.998,
<italic>P</italic>=0.035) (<xref ref-type="table" rid="t3">Table 3</xref>).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Multivariate analysis of preoperative factors.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Variable</th><th align="center" rowspan="2" colspan="1">HR</th><th align="center" colspan="2" rowspan="1">95% CI</th><th align="center" rowspan="2" colspan="1"><italic>P </italic>value</th></tr><tr><th align="center" rowspan="1" colspan="1">Lower</th><th align="center" rowspan="1" colspan="1">Upper</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Positive blood culture</td><td align="center" rowspan="1" colspan="1">4.92</td><td align="center" rowspan="1" colspan="1">0.38</td><td align="center" rowspan="1" colspan="1">63.849</td><td align="center" rowspan="1" colspan="1">0.223</td></tr><tr><td align="left" rowspan="1" colspan="1">Typical microorganism</td><td align="center" rowspan="1" colspan="1">1.304</td><td align="center" rowspan="1" colspan="1">0.154</td><td align="center" rowspan="1" colspan="1">11.064</td><td align="center" rowspan="1" colspan="1">0.808</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP</td><td align="center" rowspan="1" colspan="1">1.002</td><td align="center" rowspan="1" colspan="1">0.961</td><td align="center" rowspan="1" colspan="1">1.031</td><td align="center" rowspan="1" colspan="1">0.784</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine clearance</td><td align="center" rowspan="1" colspan="1">0.978</td><td align="center" rowspan="1" colspan="1">0.958</td><td align="center" rowspan="1" colspan="1">0.998</td><td align="center" rowspan="1" colspan="1">0.035</td></tr><tr><td align="left" rowspan="1" colspan="1">SH</td><td align="center" rowspan="1" colspan="1">5.194</td><td align="center" rowspan="1" colspan="1">1.268</td><td align="center" rowspan="1" colspan="1">21.266</td><td align="center" rowspan="1" colspan="1">0.022</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">0.997</td><td align="center" rowspan="1" colspan="1">0.951</td><td align="center" rowspan="1" colspan="1">1.046</td><td align="center" rowspan="1" colspan="1">0.915</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>CI=confidence interval; CRP=C-reactive protein; SH=systemic hypertension;
HR=hazard ratio</p></fn></table-wrap-foot></table-wrap><p>The reoperation rate was 6.8% (6 patients) in up to a 10year follow-up period, with a
mean time free of reoperation of 5.22&#x000b1;3.83 years (1.02-9.34 years, median
5.11 years); the causes of reoperation were recurrence of endocarditis in three
(50%) patients, bioprosthetic valve dysfunction in two (33.33%) and new valve lesion
in one (16.66%).</p><p>Survival curves of patients with AIE undergoing surgical treatment with and without
typical microorganisms in their preoperative blood cultures and with total surgery
times less than 435 minutes and with total surgery times greater than or equal to
435 minutes are present in <xref ref-type="fig" rid="f2">Figures 2</xref> and <xref ref-type="fig" rid="f3">3</xref>, respectively.</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Survival curves of patients with active infective endocarditis undergoing
surgical treatment with and without typical microorganisms in their
preoperative blood cultures.</p></caption><graphic xlink:href="rbccv-33-01-0032-g02"/></fig>
</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Survival curves of patients with active infective endocarditis undergoing
surgical treatment with total surgery times less than 435 minutes and
with total surgery times greater than or equal to 435 minutes.</p></caption><graphic xlink:href="rbccv-33-01-0032-g03"/></fig>
</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Surgical valve treatment for AIE is associated with high hospital mortality, which is
a consequence of complications arising from IE, especially heart failure, persistent
infection and recurrent embolism, which in turn have significant impacts on
survival<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>.</p><p>In a study of 449 patients with left-sided IE, 240 patients underwent heart valve
surgery. Surgical treatment was associated with high short-term mortality (in the
first 14 days post-operatively) (HR 3.69, 95% CI 2.17 to 6.25,
<italic>P</italic>&#x0003c;0.0001) and with decreased long-term mortality (HR 0.55, 95%
CI 0.35 to 0.87, <italic>P</italic>=0.01)<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. Despite the high hospital mortality, surgical
treatment is considered a protective factor in long-term survival analysis when
compared with clinical treatment.</p><p>In our series, a mortality rate within the first 30 postoperative days of 17.05% and
an overall mortality of 20.50% were demonstrated. These results are compatible with
those reported by Casab&#x000e9; et al.<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup> in a study of 186 IE patients, who found early
mortality in 21.8% and an overall mortality of 22.6%. Machado et
al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>
found a 30-day mortality of 17%, and Gatti et al.<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup> reported an in-hospital mortality of
20.3%.</p><p>Preoperative, intraoperative and postoperative factors are associated with a worse
prognosis in terms of both short- and long-term survival<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. Our study of the major
predictors of preoperative mortality revealed the presence of positive blood
cultures (<italic>P</italic>=0.003) and typical microorganisms
(<italic>P</italic>=0.008). Among the latter, the most frequent were
<italic>Streptococcus viridans</italic> in 12 (25%) cases and
<italic>Staphylococcus epidermidis</italic> in 10 (20.83%); these findings are
similar to those described in the literature<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r19" ref-type="bibr">19</xref>]</sup>. In this same regard,
<italic>Staphylococcus aureus</italic> has consistently been defined as an
independent risk factor for hospital death (odds ratio [OR] 2.6, 95%
CI 1.01 to 4.20)<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r20" ref-type="bibr">20</xref>,<xref rid="r21" ref-type="bibr">21</xref>]</sup>.</p><p>A study with patients on chronic hemodialysis undergoing aortic valve replacement for
AIE found a high mortality rate of 42.2% within the first 30 days
postoperatively<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. In a study by Park et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>, dialysis was a predictor
of mortality in 6 months. In our sample, only six (6.8%) patients had a history of
CKD with hemodialysis, which showed no statistically significant association with
mortality (<italic>P</italic>=0.11); however, when the creatinine and creatinine
clearance variables were analyzed, statistically significant relationships were
found (HR 1.291, 95% CI 1.108 to 1.504, <italic>P</italic>=0.01 and HR 0.977, 95% CI
0.962-0.993, <italic>P</italic>=0.005, respectively).</p><p>There has been a preponderance of males in the population of patients undergoing IE
surgery<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r15" ref-type="bibr">15</xref>]</sup>. In our study, a predominantly male population of 58
(65.9%) could be noted, consistent with the literature findings.</p><p>In this context, Dohmen et al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> evaluated long-term surgical results based on gender in
patients with AIE in the aortic valve and found a significant difference in early
mortality rate (15% among men and 23% among women, <italic>P</italic>=0.01). This
finding was not consistent with our results, which showed no significant difference
according to gender (<italic>P</italic>=0.68).</p><p>In evaluating elapsed time before surgery, in a study comparing early (before 48
hours) and conventional surgical treatment (after 48 hours), Kang et
al.<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>
observed no statistically significant difference between groups in terms of
mortality from all causes (<italic>P</italic>=0.59). In another study with 132
patients, Kim et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup> also demonstrated no statistically significant
difference in the short- and long-term survival rates of up to 5 years of followup
in early and conventional surgery subgroups. Similar results to those reported in
our study compared emergency (within 24 hours), urgent (the first 48 hours) and
elective (after 48 hours) surgeries and found no statistically significant
differences in mortality (<italic>P</italic>=0.76).</p><p>However, Casab&#x000e9; et al.<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup> demonstrated that an urgent surgical indication was
associated with a high mortality rate (<italic>P</italic>&#x0003c;0.001) in a prosthetic
valve endocarditis subgroup with an interval of &#x02264;1 year between the
surgeries.</p><p>Age and postoperative complications have emerged as mortality
predictors<sup>[<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r20" ref-type="bibr">20</xref>,<xref rid="r23" ref-type="bibr">23</xref>]</sup>. These findings are in agreement with our
results; in terms of age, every extra year increased the chance of death 1.060-fold
(HR 1.060, 95% CI 1.026 to 1.096, <italic>P</italic>=0.001), and the presence of
postoperative complications was associated with a statistically significant
difference in mortality rate (37.78% <italic>vs.</italic> 2.32%,
<italic>P</italic>=0.001). In our experience, a history of SH had a significant
impact on mortality, both in the univariate and multivariate analyses
(<italic>P</italic>&#x0003c;0.05); however, a significant association between SH and
age could be determined (<italic>P</italic>=0.0002).</p><p>In a study by Cresti et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>, septic shock and persistent bacteremia were
independent mortality predictors, consistent with our results, where shock
significantly increased in-hospital mortality rates (94.12% <italic>vs.</italic>
2.81% <italic>P</italic>=0.001). Preoperative hematological parameters are related
to poorer prognosis in IE. In a study of 62 consecutive patients with IE
procalcitonin (<italic>P</italic>=0.030) and platelet/lymphocyte ratio
(<italic>P</italic>=0.008) all significantly affected
mortality<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>, as in our study: in terms of CRP, each 1 mg/ dL
increased the chance of death 1.034-fold (HR 1.034, 95% CI 1.000 to 1.070,
<italic>P</italic>=0.04).</p><p>In current clinical practice, the EuroSCORE II is considered a useful tool in
perioperative risk assessment of AIE patients and offers good predictive
performance<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>. In our experience, EuroSCORE II (HR 1.089, 95% CI
1.030 to 1.15, <italic>P</italic>=0.003) was a significant predictor of
mortality.</p><p>Intraoperative factors are also related to lower survival. In this regard, one study
found associations between both extracorporeal circulation time
(<italic>P</italic>&#x0003c;0.0001) and aortic clamping time
(<italic>P</italic>=0.0005)<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>; these findings agree with our experience, where
length of surgery had a significant impact: every 5 minutes increased the chance of
death 1.005-fold (HR 1.005, 95% CI 1.001 to 1.009, <italic>P</italic>=0.0307), and
from 435 minutes, every 5 minutes increased the chance of death 3.903-fold (HR
3.903, 95% CI 1.508 to 10.100, <italic>P</italic>=0.005).</p><p>Our study was limited by evaluating patients treated at a single center, which
specializes in the treatment of cardiovascular disease and is considered a referral
center; it serves a larger number of patients with cardiovascular comorbidities,
among whom there is a high frequency of prior heart surgery. This frequency has an
impact on surgical risk, which explains the high hospital mortality rate. However,
our results are consistent with those reported by other studies. A total of 48.3% of
patients with prior cardiac surgery came from other centers, making it difficult to
determine the actual times between presentation of the clinical condition, diagnosis
and surgical treatment.</p><p>Because of the observational nature of the study design, the evaluation of laboratory
parameters performed routinely in the institution in the care of endocarditis
patients was limited, and it should be noted that there are other hematologic
parameters that predict risk.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>The main mortality predictors in the univariate analysis were, preoperatively,
positive blood culture, typical microorganism, CRP, creatinine clearance, age, SH
and EuroSCORE II; in the intraoperative period, total surgery time; and
postoperatively, the presence of complications, shock, sepsis and pulmonary
embolism. These factors significantly impacted short-term survival in up to a
10-year follow-up period in patients undergoing surgical treatment of AIE.</p><p>In the multivariate analysis, when the preoperative predictors positive blood
culture, typical microorganism, age, SH, creatinine clearance and CRP were compared,
only SH was a risk factor for mortality, creatinine clearance was a protective
factor and SH showed a significant association with age.</p><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">JLRO</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for important intellectual content; final approval of
the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MAS</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for important intellectual content; final approval of
the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RTA</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AR</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DDT</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SKG</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RTMK</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LCBS</td><td align="left" valign="top" rowspan="1" colspan="1">Agreement to be accountable for all
aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately
investigated and resolved; final approval of the version to be
published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Instituto Dante Pazzanese de Cardiologia,
S&#x000e3;o Paulo, SP, Brazil.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarasoutchi</surname><given-names>F</given-names></name><name><surname>Montera</surname><given-names>MW</given-names></name><name><surname>Grinberg</surname><given-names>M</given-names></name><name><surname>Pi&#x000f1;eiro</surname><given-names>DJ</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>CR</given-names></name><name><surname>Bacelar</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Brazilian Guidelines for Valve Disease - SBC 2011 / I Guideline
Inter-American Valve Disease - 2011 SIAC</article-title><source>Arq Bras Cardiol</source><year>2011</year><volume>97</volume><issue>5</issue><supplement>Suppl 1</supplement><fpage>1</fpage><lpage>67</lpage></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casab&#x000e9;</surname><given-names>JH</given-names></name><name><surname>Deschle</surname><given-names>H</given-names></name><name><surname>Cort&#x000e9;s</surname><given-names>C</given-names></name><name><surname>Stutzbach</surname><given-names>P</given-names></name><name><surname>Hershson</surname><given-names>A</given-names></name><name><surname>Nagel</surname><given-names>C</given-names></name><etal/></person-group><article-title>Predictors of hospital mortality in 186 cases of active infective
endocarditis treated in a tertiary medical center
(1992-2001)</article-title><source>Rev Esp Cardiol</source><year>2003</year><volume>56</volume><issue>6</issue><fpage>578</fpage><lpage>585</lpage><pub-id pub-id-type="pmid">12783733</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baddour</surname><given-names>LM</given-names></name><name><surname>Wilson</surname><given-names>WR</given-names></name><name><surname>Bayer</surname><given-names>AS</given-names></name><name><surname>Fowler Jr</surname><given-names>VG</given-names></name><name><surname>Tleyjeh</surname><given-names>IM</given-names></name><name><surname>Rybak</surname><given-names>MJ</given-names></name><etal/><collab>American Heart Association Committee on Rheumatic Fever,
Endocarditis, and Kawasaki Disease of the Council on Cardiovascular
Disease in the Young, Council on Clinical Cardiology, Council on
Cardiovascular Surgery and Anesthesia, and Stroke Council</collab></person-group><article-title>Infective endocarditis in adults: diagnosis, antimicrobial
therapy, and management of complications: a scientific statement for
healthcare professionals from the American Heart Association</article-title><source>Circulation</source><year>2015</year><volume>132</volume><issue>15</issue><fpage>1435</fpage><lpage>1486</lpage><pub-id pub-id-type="pmid">26373316</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habib</surname><given-names>G</given-names></name><name><surname>Lancellotti</surname><given-names>P</given-names></name><name><surname>Antunes</surname><given-names>MJ</given-names></name><name><surname>Bongiorni</surname><given-names>MG</given-names></name><name><surname>Casalta</surname><given-names>JP</given-names></name><name><surname>Del Zotti</surname><given-names>F</given-names></name><etal/></person-group><article-title>2015 ESC Guidelines for the management of infective endocarditis:
The Task Force for the Management of Infective Endocarditis of the European
Society of Cardiology (ESC). Endorsed by: European Association for
Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear
Medicine (EANM)</article-title><source>Eur Heart J</source><year>2015</year><volume>36</volume><issue>44</issue><fpage>3075</fpage><lpage>3128</lpage><pub-id pub-id-type="pmid">26320109</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheikh</surname><given-names>AM</given-names></name><name><surname>Elhenawy</surname><given-names>AM</given-names></name><name><surname>Maganti</surname><given-names>M</given-names></name><name><surname>Armstrong</surname><given-names>S</given-names></name><name><surname>David</surname><given-names>TE</given-names></name><name><surname>Feindel</surname><given-names>CM</given-names></name></person-group><article-title>Outcomes of double valve surgery for active infective
endocarditis</article-title><source>J Thorac Cardiovasc Surg</source><year>2009</year><volume>138</volume><issue>1</issue><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">19577059</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dohmen</surname><given-names>PM</given-names></name><name><surname>Binner</surname><given-names>C</given-names></name><name><surname>Mende</surname><given-names>M</given-names></name><name><surname>Bakhtiary</surname><given-names>F</given-names></name><name><surname>Etz</surname><given-names>C</given-names></name><name><surname>Pfannm&#x000fc;ller</surname><given-names>B</given-names></name><etal/></person-group><article-title>Outcome of aortic valve replacement for active infective
endocarditis in patients on chronic hemodialysis</article-title><source>Ann Thorac Surg</source><year>2015</year><volume>99</volume><issue>2</issue><fpage>532</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">25483000</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>TE</given-names></name><name><surname>Gavra</surname><given-names>G</given-names></name><name><surname>Feindel</surname><given-names>CM</given-names></name><name><surname>Regesta</surname><given-names>T</given-names></name><name><surname>Armstrong</surname><given-names>S</given-names></name><name><surname>Maganti</surname><given-names>MD</given-names></name></person-group><article-title>Surgical treatment of active infective endocarditis: a continued
challenge</article-title><source>J Thorac Cardiovasc Surg</source><year>2007</year><volume>133</volume><issue>1</issue><fpage>144</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">17198801</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bannay</surname><given-names>A</given-names></name><name><surname>Hoen</surname><given-names>B</given-names></name><name><surname>Duval</surname><given-names>X</given-names></name><name><surname>Obadia</surname><given-names>JF</given-names></name><name><surname>Selton-Suty</surname><given-names>C</given-names></name><name><surname>Le Moing</surname><given-names>V</given-names></name><etal/></person-group><article-title>The impact of valve surgery on short- and long-term mortality in
left-sided infective endocarditis: do differences in methodological
approaches explain previous conflicting results?</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><issue>16</issue><fpage>2003</fpage><lpage>2015</lpage><pub-id pub-id-type="pmid">19208650</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musci</surname><given-names>M</given-names></name><name><surname>Weng</surname><given-names>Y</given-names></name><name><surname>H&#x000fc;bler</surname><given-names>M</given-names></name><name><surname>Amiri</surname><given-names>A</given-names></name><name><surname>Pasic</surname><given-names>M</given-names></name><name><surname>Kosky</surname><given-names>S</given-names></name><etal/></person-group><article-title>Homograft aortic root replacement in native or prosthetic active
infective endocarditis: twenty-year single-center experience</article-title><source>J Thorac Cardiovasc Surg</source><year>2010</year><volume>139</volume><issue>3</issue><fpage>665</fpage><lpage>673</lpage><pub-id pub-id-type="pmid">19767017</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dohmen</surname><given-names>PM</given-names></name><name><surname>Binner</surname><given-names>C</given-names></name><name><surname>Mende</surname><given-names>M</given-names></name><name><surname>Daviewala</surname><given-names>P</given-names></name><name><surname>Etz</surname><given-names>CD</given-names></name><name><surname>Borger</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Gender-based long-term surgical outcome in patients with active
infective aortic valve endocarditis</article-title><source>Med Sci Monit</source><year>2016</year><volume>22</volume><fpage>2520</fpage><lpage>2527</lpage><pub-id pub-id-type="pmid">27427831</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheikh</surname><given-names>AM</given-names></name><name><surname>Elhenawy</surname><given-names>AM</given-names></name><name><surname>Maganti</surname><given-names>M</given-names></name><name><surname>Armstrong</surname><given-names>S</given-names></name><name><surname>David</surname><given-names>TE</given-names></name><name><surname>Feindel</surname><given-names>CM</given-names></name></person-group><article-title>Outcomes of surgical intervention for isolated active mitral
valve endocarditis</article-title><source>J Thorac Cardiovasc Surg</source><year>2009</year><volume>137</volume><issue>1</issue><fpage>110</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">19154912</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>DH</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Yun</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Long-term results of early surgery versus conventional treatment
for infective endocarditis trial</article-title><source>Korean Circ J</source><year>2016</year><volume>46</volume><issue>6</issue><fpage>846</fpage><lpage>850</lpage><pub-id pub-id-type="pmid">27826345</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JS</given-names></name><name><surname>Sexton</surname><given-names>DJ</given-names></name><name><surname>Mick</surname><given-names>N</given-names></name><name><surname>Nettles</surname><given-names>R</given-names></name><name><surname>Fowler Jr</surname><given-names>VG</given-names></name><name><surname>Ryan</surname><given-names>T</given-names></name><etal/></person-group><article-title>Proposed modifications to the Duke criteria for the diagnosis of
infective endocarditis</article-title><source>Clin Infect Dis</source><year>2000</year><volume>30</volume><issue>4</issue><fpage>633</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">10770721</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bin Abdulhak</surname><given-names>AA</given-names></name><name><surname>Tleyjeh</surname><given-names>IM</given-names></name></person-group><article-title>Indications of surgery in infective endocarditis</article-title><source>Curr Infect Dis Rep</source><year>2017</year><volume>19</volume><issue>3</issue><fpage>10</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">28251509</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>MN</given-names></name><name><surname>Nakazone</surname><given-names>MA</given-names></name><name><surname>Murad-J&#x000fa;nior</surname><given-names>JA</given-names></name><name><surname>Maia</surname><given-names>LN</given-names></name></person-group><article-title>Surgical treatment for infective endocarditis and hospital
mortality in a Brazilian single-center</article-title><source>Rev Bras Cir Cardiovasc</source><year>2013</year><volume>28</volume><issue>1</issue><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">23739930</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatti</surname><given-names>G</given-names></name><name><surname>Benussi</surname><given-names>B</given-names></name><name><surname>Gripshi</surname><given-names>F</given-names></name><name><surname>Della Mattia</surname><given-names>A</given-names></name><name><surname>Proclemer</surname><given-names>A</given-names></name><name><surname>Cannat&#x000e0;</surname><given-names>A</given-names></name><etal/></person-group><article-title>A risk factor analysis for in-hospital mortality after surgery
for infective endocarditis and a proposal of a new predictive scoring
system</article-title><source>Infection</source><year>2017</year><volume>45</volume><issue>4</issue><fpage>413</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">28054252</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>LP</given-names></name><name><surname>Chu</surname><given-names>VH</given-names></name><name><surname>Peterson</surname><given-names>G</given-names></name><name><surname>Skoutelis</surname><given-names>A</given-names></name><name><surname>Lejko-Zupa</surname><given-names>T</given-names></name><name><surname>Bouza</surname><given-names>E</given-names></name><etal/><collab>International Collaboration on Endocarditis (ICE)
Investigators</collab></person-group><article-title>Validated risk score for predicting 6-month mortality in
infective endocarditis</article-title><source>J Am Heart Assoc</source><year>2016</year><volume>5</volume><issue>4</issue><elocation-id>e003016</elocation-id><pub-id pub-id-type="pmid">27091179</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cahill</surname><given-names>TJ</given-names></name><name><surname>Baddour</surname><given-names>LM</given-names></name><name><surname>Habib</surname><given-names>G</given-names></name><name><surname>Hoen</surname><given-names>B</given-names></name><name><surname>Salaun</surname><given-names>E</given-names></name><name><surname>Pettersson</surname><given-names>GB</given-names></name><etal/></person-group><article-title>Challenges in infective endocarditis</article-title><source>J Am Coll Cardiol</source><year>2017</year><volume>69</volume><issue>3</issue><fpage>325</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">28104075</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoen</surname><given-names>B</given-names></name><name><surname>Duval</surname><given-names>X</given-names></name></person-group><article-title>Infective endocarditis</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>8</issue><fpage>785</fpage><lpage>785</lpage></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cresti</surname><given-names>A</given-names></name><name><surname>Chiavarelli</surname><given-names>M</given-names></name><name><surname>Scalese</surname><given-names>M</given-names></name><name><surname>Nencioni</surname><given-names>C</given-names></name><name><surname>Valentini</surname><given-names>S</given-names></name><name><surname>Guerrini</surname><given-names>F</given-names></name><etal/></person-group><article-title>Epidemiological and mortality trends in infective endocarditis, a
17-year population-based prospective study</article-title><source>Cardiovasc Diagn Ther</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>27</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">28164010</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>VH</given-names></name><name><surname>Cabell</surname><given-names>CH</given-names></name><name><surname>Benjamin Jr</surname><given-names>DK</given-names></name><name><surname>Kuniholm</surname><given-names>EF</given-names></name><name><surname>Fowler Jr</surname><given-names>VG</given-names></name><name><surname>Engemann</surname><given-names>J</given-names></name><etal/></person-group><article-title>Early predictors of in-hospital death in infective
endocarditis</article-title><source>Circulation</source><year>2004</year><volume>109</volume><issue>14</issue><fpage>1745</fpage><lpage>1749</lpage><pub-id pub-id-type="pmid">15037538</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Kang</surname><given-names>DH</given-names></name><name><surname>Lee</surname><given-names>MZ</given-names></name><name><surname>Yun</surname><given-names>SC</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Song</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Impact of early surgery on embolic events in patients with
infective endocarditis</article-title><source>Circulation</source><year>2010</year><volume>122</volume><issue>11</issue><fpage>S17</fpage><lpage>S22</lpage><pub-id pub-id-type="pmid">20837909</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>MA</given-names></name><name><surname>Wollmann Jr</surname><given-names>DR</given-names></name><name><surname>Campos</surname><given-names>AC</given-names></name><name><surname>Cunha</surname><given-names>CL</given-names></name><name><surname>Carvalho</surname><given-names>RG</given-names></name><name><surname>Andrade</surname><given-names>DF</given-names></name><etal/></person-group><article-title>Risk index for death by infective endocarditis: a multivariate
logistic model</article-title><source>Rev Bras Cir Cardiovasc</source><year>2007</year><volume>22</volume><issue>2</issue><fpage>192</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">17992324</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zencir</surname><given-names>C</given-names></name><name><surname>Akpek</surname><given-names>M</given-names></name><name><surname>Senol</surname><given-names>S</given-names></name><name><surname>Selvi</surname><given-names>M</given-names></name><name><surname>Onay</surname><given-names>S</given-names></name><name><surname>Cetin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association between hematologic parameters and in-hospital
mortality in patients with infective endocarditis</article-title><source>Kaohsiung J Med Sci</source><year>2015</year><volume>31</volume><issue>12</issue><fpage>632</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">26709225</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madeira</surname><given-names>S</given-names></name><name><surname>Rodrigues</surname><given-names>R</given-names></name><name><surname>Tralh&#x000e3;o</surname><given-names>A</given-names></name><name><surname>Santos</surname><given-names>M</given-names></name><name><surname>Almeida</surname><given-names>C</given-names></name><name><surname>Marques</surname><given-names>M</given-names></name><etal/></person-group><article-title>Assessment of perioperative mortality risk in patients with
infective endocarditis undergoing cardiac surgery: performance of the
EuroSCORE I and II logistic models</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2016</year><volume>22</volume><issue>2</issue><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">26547083</pub-id></element-citation></ref></ref-list></back></article>